Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (GDRX), Aclaris Therapeutics (ACRS) and Ocular Therapeutix (OCUL)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on GoodRx Holdings (GDRX – Research Report), Aclaris Therapeutics (ACRS – Research Report) and Ocular Therapeutix (OCUL – Research Report).

GoodRx Holdings (GDRX)

In a report released today, Allen Lutz from Bank of America Securities downgraded GoodRx Holdings to Sell, with a price target of $4.50. The company’s shares closed last Friday at $6.70.

According to TipRanks.com, Lutz is a 2-star analyst with an average return of 0.7% and a 50.8% success rate. Lutz covers the Healthcare sector, focusing on stocks such as Walgreens Boots Alliance, Patterson Companies, and Hims & Hers Health.

Currently, the analyst consensus on GoodRx Holdings is a Hold with an average price target of $6.55.

See today’s best-performing stocks on TipRanks >>

Aclaris Therapeutics (ACRS)

In a report released today, Julian Harrison from BTIG maintained a Buy rating on Aclaris Therapeutics, with a price target of $8.00. The company’s shares closed last Friday at $1.05, close to its 52-week low of $0.59.

According to TipRanks.com, Harrison is a 5-star analyst with an average return of 14.5% and a 54.0% success rate. Harrison covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Rani Therapeutics Holdings, and Mereo Biopharma Group Plc.

Aclaris Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $12.33, which is a 1031.2% upside from current levels. In a report issued on December 29, H.C. Wainwright also reiterated a Buy rating on the stock with a $9.00 price target.

Ocular Therapeutix (OCUL)

In a report released today, Joseph Catanzaro from Piper Sandler maintained a Buy rating on Ocular Therapeutix, with a price target of $10.00. The company’s shares closed last Friday at $4.46.

According to TipRanks.com, Catanzaro is a 4-star analyst with an average return of 6.6% and a 42.1% success rate. Catanzaro covers the Healthcare sector, focusing on stocks such as Black Diamond Therapeutics, Day One Biopharmaceuticals, and Turnstone Biologics Corp.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ocular Therapeutix with a $12.00 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on GDRX:

• Jefferies specialty pharmaceuticals analyst has analyst/industry conference call
• GoodRx management to meet virtually with KeyBanc
• CVS CostVantage to lower value proposition offered by GoodRx, says Wells Fargo
• Hims & Hers weight loss solution ‘will be welcomed,’ says Citi
• GoodRx interim CEO Wagner buys $180K in common stock